Series A Funded Biotechnology Startups
Among disclosed Series A rounds in biotechnology, cAMPfield Therapeutics’ $180M (2026-05-20) sits far above the rest, with Beeline Medicines at $126M (2026…
Among disclosed Series A rounds in biotechnology, cAMPfield Therapeutics’ $180M (2026-05-20) sits far above the rest, with Beeline Medicines at $126M (2026-06-30) and Coultreon Biopharma at $125M (2026-04-28) forming the next tier. Several other disclosed deals cluster between roughly $83M and $113M (e.g., Cytospire Therapeutics $83M on 2026-05-05, Tortugas Neuroscience $106M on 2026-04-21), while the smallest disclosed amount is $1M for Gel-Coat Biomaterials (2026-04-22).
Timing is concentrated: dates span 2026-03-09 to 2026-07-13, and the list contains multiple entries in the same late-spring/early-summer window (e.g., 2026-05-05, 2026-05-27, 2026-06-01). Geographically, London (4) and Cambridge (4) appear more than once, alongside New York (3), suggesting hub-like repeat locations rather than evenly distributed offices across countries.
Most recent rounds
50 of 561511 more funded startups
This page shows the 50 most recent rounds (back to Mar 2026). The full 561-company history for this listing is available on a paid plan.
Unlock all 561 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What does the size distribution look like for these recent biotech Series A rounds?
The largest disclosed round is cAMPfield Therapeutics’ $180M on 2026-05-20, and the next-largest disclosed deals are Beeline Medicines ($126M on 2026-06-30) and Coultreon Biopharma ($125M on 2026-04-28). At the low end, Gel-Coat Biomaterials raised $1M on 2026-04-22, with multiple other disclosed rounds below $20M (e.g., Dioseve at $6M on 2026-06-11).
Are there notable date clusters in the most recent 50 rows?
Yes. Several rounds land in tight windows across late May and early June, including 2026-05-27 (Ember LifeSciences is undisclosed; Pacifico Biolabs $8M; Secretome Therapeutics $30M; Waypoint Bio $20M) and 2026-06-01 (IMU Biosciences $38M; Oak hill bio $33M). The overall range runs from 2026-03-09 to the most recent 2026-07-13 (ArcGen Bioscience at $7M).
Which cities appear most often, and do any locations repeat at scale?
London appears 4 times and Cambridge appears 4 times, with New York appearing 3 times across the 50 rows. Examples include London-based entries such as Alchemab Therapeutics ($34M, 2026-07-09) and RQ Bio ($113M, 2026-06-24), plus Cambridge-based deals like IMU Biosciences (London) contrast with Stipple Bio ($100M, 2026-04-06, Cambridge) and Immutrin ($87M, 2026-03-24).
How many rounds are undisclosed, and does the presence of undisclosed amounts affect the outlier analysis?
Undisclosed amounts appear in 2 of the 50 rows (e.g., Aton Health on 2026-06-12 and Ember LifeSciences on 2026-05-27). The largest and smallest comparisons above are based on disclosed amounts only, where the top disclosed is $180M (cAMPfield Therapeutics, 2026-05-20) and the smallest disclosed is $1M (Gel-Coat Biomaterials, 2026-04-22).
Which disclosed rounds form the top tier worth prioritizing for commercial outreach or diligence?
The top tier of disclosed amounts (ranked) includes cAMPfield Therapeutics at $180M (2026-05-20), Beeline Medicines at $126M (2026-06-30), Coultreon Biopharma at $125M (2026-04-28), and RQ Bio at $113M (2026-06-24). Additional high-end entries are Tortugas Neuroscience at $106M (2026-04-21) and Stipple Bio at $100M (2026-04-06).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.